Blc2 is a prognosticator for IDC

Hopeful · 07-23-2007, 07:28 AM

The article: http://www.breastcancersource.com/br..._27859___.aspx

The abstract: http://annonc.oxfordjournals.org/cgi...ract/18/6/1004

Of interest:

"Results: In the entire series, the Bcl2 variable was an independent predictor of clinical outcome, and its prognostic independence was maintained when lymph node-negative and -positive patients were considered separately. In this regard, of particular interest was the observation of a subgroup of node-negative breast cancer patients with a negative Bcl2 immunostaining, who had a very high probability of relapse or death (respectively about five and seven times greater than patients with a positive Bcl2 immunostaining). Moreover, the Bcl2 variable retained prognostic significance also in subgroups of patients treated with either adjuvant endocrine therapy or chemotherapy."


Hopeful